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Introduction
============

Multiple recent studies have suggested an increased incidence of de novo and recurrent hepatocellular carcinoma (HCC) in cirrhotic patients with a sustained virologic response (SVR) after completing therapy with direct-acting antivirals (DAAs) \[[@REF1]-[@REF4]\]. Recent studies also suggest lower SVR rates in patients with hepatitis C virus (HCV)-related cirrhosis and underlying HCC when compared to patients with only HCV cirrhosis \[[@REF5]\]. In the hope of adding to the literature, we performed a retrospective analysis to assess the rates of SVR and the incidence and recurrence of HCC in chronic HCV-infected patients who were treated with DAAs at our institution.

Materials and methods
=====================

We analyzed 497 HCV-infected patients who were treated with DAAs, or a combination of DAA with interferon, from January 2014 to April 2017 at the Veterans Medical Center, Oklahoma City. Descriptive analysis, including the mean and standard deviation for different variables, was used. The cohort was divided into two groups: cirrhotic and non-cirrhotic. The analysis was run in the cirrhotic group between the subgroups who developed HCC and who did not. ​​​​​​​A P value \< 0.05 was considered statistically significant.

Results
=======

Two hundred and thirty-three patients (46.88 %) had cirrhosis, of which 16 (6.86%) developed HCC (11 de novo and five recurrent cases) during or after DAA therapy was initiated, whilst the remaining 217 (93.1%) cirrhotic patients did not develop HCC. None of the non-cirrhotic patients developed HCC. We further subdivided the cirrhotic group into those who eventually were diagnosed with HCC (group 1) and those who were not (group 2). These subgroups were comparable in regards to race, gender, baseline serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), platelets, sodium, HCV genotypes, and pretreatment viral load. All patients completed therapy. The rate of SVR was much lower in group 1 compared to group 2 (62.5% vs 88.94%, p = 0.002), respectively. The Fibrosis-4 (FIB-4) score was higher in group 1 as compared to group 2 (7.88 vs 4.09, p = 0.048), respectively. The average time period (weeks) from completion of DAA therapy to HCC diagnosis was 48.2 weeks and from time of SVR to HCC detection was 33.3 weeks (Table [1](#TAB1){ref-type="table"}).

###### Table: Comparative analysis between cirrhotic patients with and without hepatocellular carcinoma.

Demographic and laboratory variables along with outcome assessment with Chi-Square Test or T-test. Acronyms: Hepatocellular carcinoma (HCC), Hepatitis C Virus (HCV), Aferican American (AA), Model for End-Stage Liver Disease (MELD), Child-Turcotte-Pugh (CTP), Fibrosis-4 (FIB-4) Score, sustained virological response (SVR), Interfron (IFN), and direct acting antiviral (DAA).

  ----------------------------------------------------- -------------------------------------------------- ------------------------------------------------------ ---------
  Variables                                             HCV treated cirrhotic patients with HCC (n = 16)   HCV treated cirrhotic patients without HCC (n = 217)   P-Value
  AGE, average                                          66.19                                              62.09                                                  0.005
  Male sex, n (%) \[number & percentage of patients\]   16 (100)                                           212 (97.7)                                             0.539
  RACE                                                                                                                                                             
  a\. White, n (%)                                      12 (75)                                            155 (71.43)                                            0.913
  b\. AA, n (%)                                         2 (12.5)                                           26 (11.98)                                              
  c\. Other, n (%)                                      2 (12.5)                                           36 (16.59)                                              
  HCV Genotype                                                                                                                                                    0.624
  a\. Genotype 1a                                       9 (56.25)                                          108 (49.76)                                             
  b\. Genotype 1b                                       3 (18.75)                                          44 (20.27)                                              
  c\. Genotype 2                                        2 (12.5)                                           46 (21.19)                                              
  d\. Genotype 3                                        2 (12.5)                                           2 (0.92)                                                
  History of alcohol, n (%)                             10 (62.5)                                          212 (97.69)                                            \<0.001
  History of smoking, n (%)                             11 (68.75)                                         181 (83.4)                                             0.113
  History of IV drug use, n (%)                         5 (31.25)                                          139(64)                                                \<0.001
  Pre-Treatment Viral Load (IU/ml) Mean Value           1,286,176                                          4,484,995                                              0.084
  Patients achieving SVR, n (%)                         10 (62.5)                                          193 (88.94)                                            0.002
  MELD Score, mean (median) at SVR                      11.31(11)                                          9.88 (9)                                               0.173
  CTP Score at SVR, mean (median)                       6.31(6)                                            5.73 (5)                                               0.064
  FIB-4 Score at SVR, mean (median)                     7.88 (6.52)                                        4.98 (2.96)                                            0.048
  AST at SVR, mean (median)                             62.81 (48)                                         40.33 (28)                                             0.104
  ALT at SVR, mean (median)                             45.75 (29)                                         31.55 (23)                                             0.201
  Hemoglobin at SVR, mean (median)                      13.06 (13.05)                                      14.09 (14.5)                                           0.045
  T. Bilirubin at SVR, mean (median)                    1.53 (1.3)                                         1.03 (0.8)                                             0.005
  Albumin at SVR, mean (median)                         3.23 (3.2)                                         3.73 (3.8)                                             \<0.001
  Na at SVR                                             136.69 (137)                                       142.04 (137)                                           0.758
  Platelets at SVR                                      108.75(96.5)                                       132.84(130.5)                                          0.173
  Treatment naïve/Non-Treatment Naïve, n (%)                                                                                                                      0.005
  a\. Treatment naïve, n (%)                            6 (37.5)                                           155 (71.43)                                             
  b\. Non-Treatment naïve, n (%)                        10 (62.5)                                          62 (28.57)                                              
  Treatment regimen, n (%)                                                                                                                                         
  a\. DAA only based regimen, n (%)                     13 (81.25)                                         207 (95.39)                                             
  b\. DAA & IFN based regimens, n (%)                   3 (18.75)                                          10 (4.6)                                                
  c\. Use of Ribavirin, n (%)                           12 (75)                                            115 (52.99)                                             
  Comorbidities due to Chronic Liver Disease                                                                                                                       
  a\. Ascites, n (%)                                    2 (12.5)                                           14 (6.48)                                              0.359
  b\. Esophageal Varices, n (%)                         8 (50)                                             47 (21.66)                                             0.01
  ----------------------------------------------------- -------------------------------------------------- ------------------------------------------------------ ---------

Discussion
==========

According to the Centers for Disease Control (CDC), of patients infected with hepatitis C, 5% - 20% develop cirrhosis over 20-30 years. Of these, 1% - 5 % die due to decompensated cirrhosis or HCC. Unadjusted data from a study conducted over a course of a decade (2001 - 2013) in United States veterans, published in November 2015, showed an incidence of HCC increased by 265%, mortality in cirrhotics increased by 51% and by 285% in patients with HCC \[[@REF6]\]. With this global burden of hepatitis C, DAA-based regimens, with high efficacy and optimal safety profiles, are the best treatment option to date. However, recent studies have questioned the safety profile of these DAAs \[[@REF2], [@REF7]-[@REF8]\]. A proposed hypothesis is the disruption of immune surveillance after starting DAA-based antiviral therapy \[[@REF3]\]. At the other end of the spectrum, analysis of three French prospective multicenter cohorts, a prospective observational study, and analysis of a retrospective cohort of HCV-infected veterans treated with DAAs all showed no increase in HCC recurrence in patients treated with DAAs \[[@REF4], [@REF9]-[@REF10]\]. Recent studies also demonstrate a lower SVR in HCV cirrhotics with underlying HCC. There are numerous proposed mechanisms for this, including HCC acting as a reservoir for HCV replication, distorted liver architecture due to HCC, lack of delivery of DAAs into HCC, different resistant strains of HCV infected patients with HCC, and immune dysregulation \[[@REF5]\].

Conclusions
===========

As per our comparison, achieving SVR in cirrhotic patients should not preclude HCC screening and more studies are needed to assess the risk of HCC in patients who achieve SVR but have a high FIB-4 Score. In fact, patients who do not achieve SVR, may be at a higher risk of eventually developing HCC, and may be candidates for closer surveillance. Affirmative conclusions cannot be drawn based on the nature of all studies to date but it reinforces the need for statistically stronger studies on larger cohorts that takes into account all the flaws of previous studies. In this current era of questionable association of DAAs with HCC, ongoing HCC surveillance in cirrhotics achieving SVR from DAAs is a reasonable approach until we get further clarification.
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